Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Product/Service, Survey, Award

Horizon Therapeutics plc Ranked #1 in Overall Corporate Reputation Among U.S. Patient Groups that Report Working with the Company


Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked #1 in overall corporate reputation among U.S. patient groups that reported working with the company, and #2 in overall corporate reputation among U.S. patient groups familiar with the company. These results are based on PatientView's annual survey of 207 U.S. patient groups who evaluated 38 pharmaceutical and biotechnology companies.

"Every day our patient advocacy team is working with patient groups to support their efforts toward improving the lives of people living with some of the most challenging diseases," said Matt Flesch, vice president, patient advocacy and communications, Horizon. "To be recognized by these patient groups who we have learned so much from ? and whose insights have guided nearly every facet of our work ? is an honor. We are humbled by the feedback provided within the PatientView report and look forward to continued opportunities to support the transformative work led by patient advocacy organizations around the world."

U.S. Report Highlights

The PatientView U.S. report is based on an annual survey on the reputational status of the pharmaceutical industry and individual companies from the perspective of U.S. patient groups.

The report provides two sets of rankings: one based on responses from groups who reported working with the company, and one based on responses from groups who are familiar with the company.

Among patient groups who reported working with Horizon, the company ranked #1 for:

Patient groups familiar with the company ranked Horizon #1 in having an effective patient-centered strategy, providing high-quality information for patients and transparency in funding stakeholders.

Global Report Highlights

In April 2021, Patient View reported global results on the reputational status of the pharmaceutical industry and individual companies from the perspective of patient groups worldwide.

Horizon's Commitment to Disease Communities

Horizon is committed to improving people's lives by identifying and bringing to market medicines that address unmet medical needs; the company's commitment to patients extends beyond its medicines. In 2020, Horizon actively partnered with more than 100 organizations to raise awareness for many underrepresented diseases and to advocate on behalf of patients and their communities.

Company highlights from 2020 include:

About Horizon

Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.


These press releases may also interest you

at 17:20
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...

at 17:12
YMCA's Boys and Young Men of Color (BYMOC) is pleased to announce a partnership with Old Spice's School of Swagger to help boys of color graduate high school via mentorship and career planning. This partnership will enable the nationwide expansion of...

at 17:05
Spirit Blockchain Capital ("SBC" or the "Company") , is pleased to announce it has closed the first tranche of its previously announced non-brokered private placement (the "Offering") of units ("Units") and convertible promissory notes ("Notes") for...

at 17:05
Today Domo announced at Domopalooza: the AI + Data Conference that App Studio, Domo's low-code app builder, is now generally available. The company also announced that it has bolstered its low-code automation engine Workflows, streamlining and...

at 17:05
Sirona Biochem Corp. ("Sirona") announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in...

at 17:00
via IBN - Nilam Resources, Inc. today announced that it has appointed Pranjali More as Interim Chief Executive Officer and addresses current developments regarding trading status and the status of the agreement with Xyberdata and Mindwave. Prior to...



News published on and distributed by: